Noxopharm Ltd
Noxopharm Ltd is a biotechnology company focused on the development of novel therapies for the treatment of cancer, primarily through its lead product candidate, Lurbinectedin, which is being evaluated for the treatment of small cell lung cancer and other solid tumors.
Business. Noxopharm Ltd (NOX.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Noxopharm Ltd (NOX.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Noxopharm Ltd has a basic and diluted share count of 307,237,950, indicating no immediate dilution pressure from share issuance. However, the company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
The company's financial performance is not yet characterized by profitability or returns metrics, as the valuation snapshot does not provide data on profitability or return on invested capital. The company is in the development stage, and its financials are not yet comparable to industry medians for profitability metrics.
Noxopharm's revenue is not segmented by geographic region or product in the available data, and the company's exposure to different markets is not disclosed. The company's operations are primarily focused on the development of its lead product candidate, Lurbinectedin.
The company's growth trajectory is not quantified in the available data, but the last actual revenue reported was 5,450,590 AUD. The company is in the early stages of commercialization, and its future revenue growth will depend on the regulatory approval and commercial success of its lead product candidate.
The company's risk assessment indicates a low dilution risk, but liquidity risk could not be assessed due to the lack of balance-sheet inputs. The company has not disclosed any dilution events or financing activities in the source documents.
Recent events for Noxopharm Ltd include the reporting of its last actual revenue of 5,450,590 AUD. The company is in the process of advancing its lead product candidate through clinical trials, but no recent filings or transcripts are available to provide further insight into its operations or strategic direction.
- Noxopharm Ltd is a biotechnology company focused on the development of Lurbinectedin for the treatment of cancer.
- The company has a basic and diluted share count of 307,237,950, indicating no immediate dilution pressure.
- Noxopharm's liquidity position could not be assessed due to the absence of balance-sheet inputs.
- The company's last actual revenue was 5,450,590 AUD, and it is in the early stages of commercialization.
- The company's risk assessment indicates a low dilution risk, but liquidity risk could not be assessed.
- "margin_outlook_rationale": "The company's margin outlook is not available due to the lack of profitability data in the source documents.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$2.8M, +17,5% YoY; Operating income −17,1% YoY.
- ▍Revenue A$2.8M, +17,5% YoY
- ▍Operating income −17,1% YoY
- ▍Net income −36,5% YoY
- ▍Free cash flow −36,5% YoY
- ▍Net margin -172.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Noxopharm Ltd Market data — financials · 2026-05-28
- Noxopharm Ltd Market data — analyst estimates · 2026-05-28